Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
466.01
+5.28 (1.15%)
At close: Oct 30, 2026, 4:00 PM EDT
466.40
+0.39 (0.08%)
After-hours: Oct 30, 2026, 7:54 PM EDT
Amgen Market Cap
Amgen has a market cap or net worth of $251.94 billion as of October 30, 2026. It is the 69th most valuable company in the world and the 46th biggest in the United States. Its market cap has increased by 60.39% in one year.
Market Cap
251.94B
Enterprise Value
295.25B
1-Year Change
60.39%
Global Rank
Country Rank
#46 United States
Category
ChartMarket Cap Chart
Since December 1, 1998, Amgen's market cap has increased from $19.50B to $251.94B, an increase of 1,191.82%. That is a compound annual growth rate of 9.59%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 30, 2026 | 251.94B | 42.94% |
| Dec 31, 2025 | 176.25B | 25.80% |
| Dec 31, 2024 | 140.10B | -9.11% |
| Dec 29, 2023 | 154.14B | 9.99% |
| Dec 30, 2022 | 140.14B | 10.59% |
| Dec 31, 2021 | 126.72B | -5.33% |
| Dec 31, 2020 | 133.85B | -6.55% |
| Dec 31, 2019 | 143.24B | 15.47% |
| Dec 31, 2018 | 124.05B | -1.73% |
| Dec 29, 2017 | 126.24B | 16.06% |
| Dec 30, 2016 | 108.77B | -11.17% |
| Dec 31, 2015 | 122.45B | 1.06% |
| Dec 31, 2014 | 121.17B | 40.84% |
| Dec 31, 2013 | 86.03B | 30.06% |
| Dec 31, 2012 | 66.15B | 17.52% |
| Dec 30, 2011 | 56.28B | 8.51% |
| Dec 31, 2010 | 51.87B | -9.41% |
| Dec 31, 2009 | 57.26B | -6.42% |
| Dec 31, 2008 | 61.19B | 21.14% |
| Dec 31, 2007 | 50.51B | -36.61% |
| Dec 29, 2006 | 79.68B | -18.14% |
| Dec 30, 2005 | 97.34B | 19.46% |
| Dec 31, 2004 | 81.48B | 2.22% |
| Dec 31, 2003 | 79.71B | 28.11% |
| Dec 31, 2002 | 62.22B | 5.44% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Johnson & Johnson | 657.68B |
| AbbVie | 521.11B |
| Merck & Co. | 368.89B |
| Novartis AG | 306.70B |
| AstraZeneca | 290.07B |
| Gilead Sciences | 211.70B |
| Novo Nordisk | 175.43B |
| Pfizer | 173.95B |